ProCrysta Biologix, Inc. is involved in strategic collaborative partnership for research in various areas such as purification, formulation and drug delivery of bio-molecules using its proprietary crystallization technology. ProCrysta’s unparalleled technology can produce unique intellectual opportunity for the formulation of biologics and to improve health and patient compliance. In addition, the company is dedicated to develop and commercialize novel protein therapeutics for the treatment of infectious diseases and metabolic disorders with unmet medical needs. The company's innovative approach focuses on designing of effective protein therapies and on drug delivery options for oral, subcutaneous, topical and pulmonary routes using its crystallization technology. ProCrysta's lead product PCB-101 is a novel enzyme therapy for the treatment of tuberculosis, part of this program was funded by National Institutes of Health (NIH).

We have expertise in protein crystallization and formulation development. Crystalline protein formulations are stable and beneficial to turn infusion formulations to subcutaneous formulations.